← Drug database

Trajenta (linagliptin)

Region
🇪🇺 EU
Active substance
linagliptin
Company
Boehringer Ingelheim International GmbH
Status
Authorised
Therapeutic area
Diabetes Mellitus, Type 2
EU approval
Tue 23 Aug 2011
Application
EMEA/H/C/002110
ATC
A10BH05
Official record
www.ema.europa.eu

Indication

Trajenta is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults: as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment. as combination therapy in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

Follow Trajenta

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.